{"entity":{"id":"repertoire-immune-medicines","kind":"company","name":"Repertoire Immune Medicines","aka":["Repertoire Immune Medicines, Inc.","Repertoire"],"tldr":"Repertoire Immune Medicines designs off-the-shelf medicines that steer the body's T cells to a marker found on cancer cells. Its lead, RPTR-1-201, is in an early trial in advanced solid tumours and has FDA Fast Track status for triple-negative breast cancer.","summary":"Repertoire Immune Medicines was founded in 2019 by Flagship Pioneering and operates in Cambridge, Massachusetts, and Zurich. Its DECODE platform maps T cell receptor (TCR) and epitope pairs from tumour-infiltrating T cells to design TCR bispecifics (an engineered TCR joined to an anti-CD3 domain that redirects T cells to tumour cells) and off-the-shelf mRNA cancer vaccines; it also develops tolerising therapies for autoimmune disease. Its lead, RPTR-1-201, is in a phase 1/2 trial alone and with an anti-PD-1 antibody in advanced solid tumours (NCT07293754), with cohorts listed for microsatellite-stable colorectal cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast, pancreatic, gastric, bladder, cervical and oesophageal cancer. In May 2026 the FDA granted Fast Track designation to RPTR-1-201 for HLA-A*02:01-positive adults with unresectable or metastatic triple-negative breast cancer after standard therapies. Earlier programmes in development include RPTR-1-301 (HPV-positive cancers), RPTR-1-004 (prostate cancer) and half-life-extended RPTR-1-005 and RPTR-1-006. The company has partnerships with Bristol Myers Squibb, Genentech, Pfizer and Eli Lilly.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.repertoire.com/"},{"label":"Pipeline","url":"https://www.repertoire.com/programs/pipeline"},{"label":"Approach to cancer","url":"https://www.repertoire.com/platforms/approach-in-cancer"},{"label":"RPTR-1-201 Fast Track release (May 2026)","url":"https://www.repertoire.com/about/press-releases/repertoire-immune-medicines-announces-fda-fast-track-designation-for-its-investigational-immune-medicine-rptr-1-201"},{"label":"RPTR-1-201 trial NCT07293754","url":"https://clinicaltrials.gov/study/NCT07293754"}],"tags":[],"related":[],"cancers":["tnbc","colorectal","nsclc","head-and-neck","pancreatic","gastric","urothelial","cervical","esophageal"],"sections":["immunotherapy"],"technologies":["t-cell-engager","shared-antigen-vaccine"],"targets":["cd3"],"drugs":["rptr-1-201"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07293754"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Financing amounts not read from a company source, so no funding rows are given.","Repertoire's earlier trials (RPTR-147, NCT03815682 from 2018; RPTR-168, NCT04762225) were terminated; NCT03815682 predates the stated 2019 founding and is not linked. Of its trials only NCT07293754 (RPTR-1-201) has an OnCo trial record, linked here.","RPTR-1-201 requires HLA-A*02:01 in the Fast Track indication; the epitope target is not named.","The Flagship company page returned a bot-check page and was not read; Flagship rests on the company's own statement that it was founded by Flagship."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.repertoire.com/","founded":2019,"stage":"growth","investors":["flagship-pioneering"],"funding":[]},"route":"/companies/repertoire-immune-medicines/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"rptr-1-201","kind":"drug","name":"RPTR-1-201","route":"/drugs/rptr-1-201/"}],"trial":[{"id":"nct07293754","kind":"trial","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","route":"/trials/nct07293754/"}],"company":[{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/"}]}}